CHRS (Coherus Oncology) Institutional Ownership: 38.32% (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHRS Coherus Oncology Inc CHRS
42 GF Score
Price $1.27
GF Value $0.94
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Coherus Oncology Institutional Ownership?

Coherus Oncology CHRS +0.40% 42 Institutional Ownership is 38.32% as of Aug. 08, 2026. GuruFocus rates CHRS with a GF Score™ of 42/100 and a GF Value™ of $0.94 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Coherus Oncology's institutional ownership is 38.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Coherus Oncology's Insider Ownership is 1.37%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Coherus Oncology's Float Percentage Of Total Shares Outstanding is 97.05%.

Coherus Oncology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology Institutional Ownership Chart

Coherus Oncology Historical Data

The historical data trend for Coherus Oncology can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 26.96 26.77 26.69 26.73 27.21 22.11 21.94 21.74 23.37 23.34
CHRS
42GF Score
Coherus Oncology Inc CHRS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coherus Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 38.32% mean?
Coherus Oncology (CHRS) has a Institutional Ownership of 38.32% as of Aug. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Coherus Oncology and its competitors.
Is Coherus Oncology's Institutional Ownership too high?
Coherus Oncology's current Institutional Ownership is 38.32%. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Institutional Ownership compare to NAUT and AVXL?
Coherus Oncology's Institutional Ownership of 38.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Institutional Ownership is 38.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.94, compared to a current price of $1.27 — trading 35.1% above its estimated fair value. The current Institutional Ownership is 38.32%. Coherus Oncology's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current Institutional Ownership is 38.32% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (CHRS) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of $1.27 is trading 35.1% above its estimated GF Value™ of $0.94. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for CHRS:

  • Institutional Ownership: 38.32%
  • GF Value™: $0.94 vs. price of $1.27 (35.1% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges 8C5:Germany
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score

Get the complete analysis for CHRS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price
$0.94
GF Value